Catalyst Wire Dossier Catalyst Wire Dossier

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Interleukin-2
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2, covering 2021-02-23 to 2021-02-23. Get the full timeline:

Most recent: Clinical Trial Update: A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2 [Phase 4]

See pricing